サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414542

関節リウマチ治療薬の世界市場レポート 2024年

Rheumatoid Arthritis Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
関節リウマチ治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

関節リウマチ治療薬市場規模は近年わずかながら成長しています。2023年の608億2,000万米ドルから2024年には610億6,000万米ドルに、CAGR0.4％で拡大します。過去の期間に見られた拡大は、疾病の有病率の上昇、医療インフラの進歩、認知度の向上と教育的努力、政府の取り組みと支援、戦略的提携など、いくつかの要因によるものです。

関節リウマチ治療薬市場規模は、今後数年間でわずかな成長が見込まれます。2028年の年間平均成長率（CAGR）は1.5％で、648億6,000万米ドルに成長します。予測期間中に拡大が見込まれる主要要因は、個別化医療の普及動向、新興国市場の急成長、パイプライン開拓の進行、併用療法の協調的重視、医療支出の顕著な増加です。予測期間を形成すると予想される主要動向には、生物学的療法の支配的な役割、バイオシミラーの影響、個別化医療の進展、経口療法の急成長、早期診断と早期介入への注目の高まりが含まれます。

予想される関節炎患者の急増は、今後数年間における関節リウマチ治療薬市場の拡大を牽引する構えです。関節リウマチは、健康な細胞にダメージを与え、痛みを伴う腫れを引き起こす自己免疫反応や炎症反応を特徴とし、薬剤や自己管理技術の形で効果的な治療選択肢があります。これらの介入は、痛みを軽減し、関節の柔軟性を改善し、病気の進行を妨げることを目的としています。注目すべきは、米国疾病予防管理センター（CDC）が発表した最近のデータで、2021年に米国で診断された成人の関節炎患者数は5,440万人、2040年には7,800万人に達すると予測され、関節炎の症例が大幅に増加していることが明らかになったことです。その結果、関節炎の有病率の増加が関節リウマチ治療薬市場の主要な促進要因になると予想されます。

高齢者人口の拡大は、関節リウマチ治療薬市場の成長に大きく貢献すると予想されます。高齢者人口とは、生産年齢人口（18～64歳）に対する65歳以上の人口を指します。高齢者の関節リウマチ治療には課題とチャンスがあり、JAK阻害剤や標的合成DMARDsなどの新薬は、この層にとってより安全なプロファイルを持つ可能性のある代替選択肢を提供しています。ReliefWebが2022年7月に報告したように、世界の65歳以上の人口は2022年の10％から2050年には16％に増加し、9,400万人に達し、総人口の23％を占めると予測されています。したがって、高齢者人口の増加は関節リウマチ治療薬市場を推進する重要な要因です。

2023年の関節リウマチ治療薬市場では北米が最大地域でした。北米は、予測期間中、世界の関節リウマチ市場レポートにおいて最も急成長する地域となる見込みです。関節リウマチ治療薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の関節リウマチ治療薬市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の関節リウマチ治療薬の市場規模実績と成長、2018～2023年
  • 世界の関節リウマチ治療薬市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界の関節リウマチ治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 非ステロイド性抗炎症薬（NSAID）
  • コルチコステロイド
  • 疾患修飾性抗リウマチ治療薬（DMARD）
  • 生物学的応答修飾因子（BRM）
  • その他
  • 世界の関節リウマチ治療薬市場、投与経路別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 経口
  • 非経口
  • 局所
  • その他
  • 世界の関節リウマチ治療薬市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域と国の分析

  • 世界の関節リウマチ治療薬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
  • 世界の関節リウマチ治療薬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 関節リウマチ治療薬市場の競合情勢
  • 関節リウマチ治療薬市場の企業プロファイル
    • Pfizer Inc.
    • AbbVie Inc.
    • Amgen Inc.
    • Novartis AG
    • Boehringer Ingelheim International GmbH

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の展望と潜在性分析

第35章 付録

目次
Product Code: r12052

“Rheumatoid Arthritis Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rheumatoid arthritis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rheumatoid arthritis drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The rheumatoid arthritis drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids; Disease-Modifying Antirheumatic Drugs (DMARDs); Biologic Response Modifiers (BRMs); Other Drug Types
  • 2) By Route Of Administration: Oral; Parenteral; Topical; Other Route Of Administrations
  • 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
  • Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Amgen Inc.; Novartis AG; Boehringer Ingelheim International GmbH
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Rheumatoid arthritis pharmaceuticals encompass medications designed for the management of an autoimmune disorder characterized by symptoms such as inflammation in the vicinity of joint tissues. These drugs aim to mitigate lasting damage to joints and other tissues while impeding the progression of rheumatoid arthritis.

The primary categories of rheumatoid arthritis pharmaceuticals consist of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), biologic response modifiers (BRMs), and other pharmaceutical classifications. NSAIDs, a subset of these drugs, are utilized for alleviating inflammation, fever, and other inflammatory conditions, offering advantages over steroids by minimizing adverse effects. Administration routes include oral, parenteral, topical, and alternative methods. The distribution channels for rheumatoid arthritis drugs encompass hospital pharmacies, retail pharmacies, and online pharmacies..

The rheumatoid arthritis drugs market research report is one of a series of new reports from The Business Research Company that provides rheumatoid arthritis drugs market statistics, including rheumatoid arthritis drugs industry global market size, regional shares, competitors with a rheumatoid arthritis drugs market share, detailed rheumatoid arthritis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the rheumatoid arthritis drugs industry. This rheumatoid arthritis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rheumatoid arthritis drugs market size has grown marginally in recent years. It will grow from $60.82 billion in 2023 to $61.06 billion in 2024 at a compound annual growth rate (CAGR) of 0.4%. The expansion observed in the historical period can be ascribed to several factors, including the rising prevalence of diseases, advancements in healthcare infrastructure, increased awareness and educational efforts, governmental initiatives and support, as well as strategic collaborations.

The rheumatoid arthritis drugs market size is expected to see marginal growth in the next few years. It will grow to $64.86 billion in 2028 at a compound annual growth rate (CAGR) of 1.5%. The anticipated expansion during the forecast period is primarily driven by the prevailing trends in personalized medicine, the burgeoning growth of emerging markets, ongoing advancements in pipeline development, a concerted emphasis on combination therapies, and a notable rise in healthcare expenditure. Key trends expected to shape the forecast period encompass the dominant role of biological therapies, the impact of biosimilars, advancements in personalized medicine, the burgeoning growth of oral therapies, and a heightened focus on early diagnosis and intervention.

The anticipated surge in arthritis cases is poised to drive the expansion of the rheumatoid arthritis drugs market in the coming years. Rheumatoid arthritis, characterized by autoimmune and inflammatory responses causing damage to healthy cells and resulting in painful swelling, has effective treatment options in the form of drugs and self-management techniques. These interventions aim to reduce pain, improve joint flexibility, and impede the progression of the disease. Notably, recent data from the Centers for Disease Control and Prevention (CDC) highlights a significant rise in arthritis cases, with 54.4 million adults diagnosed in the United States in 2021, projected to reach 78 million by 2040. Consequently, the increasing prevalence of arthritis is expected to be a key driver for the rheumatoid arthritis drug market.

The expanding elderly population is anticipated to contribute significantly to the growth of the rheumatoid arthritis drugs market. The term "elderly population" denotes individuals aged 65 and above, relative to the working-age population (18 to 64 years old). Managing rheumatoid arthritis in the elderly presents challenges and opportunities, with newer drugs such as JAK inhibitors and targeted synthetic DMARDs offering alternative options with potentially safer profiles for this demographic. As reported by ReliefWeb in July 2022, the global population of individuals aged 65 or older is projected to increase from 10% in 2022 to 16% in 2050, reaching 94 million and comprising 23% of the total population. Hence, the growth of the elderly population is a key factor propelling the rheumatoid arthritis drugs market.

The rheumatoid arthritis drug market is witnessing a notable trend in product innovations, with companies strategically embracing new product launches to maintain and enhance their market positions. One such example is the introduction of Olokizumab by R-Pharm, a Russian high-tech pharmaceutical company, in August 2022. Olokizumab is a humanized monoclonal antibody targeting the cytokine interleukin-6, a key player in the progression of joint destruction in rheumatoid arthritis. This innovative product, similar to TNF (tumor necrosis factor), mitigates inflammatory responses, thereby reducing disease activity in many rheumatoid arthritis patients.

Major players in the rheumatoid arthritis drug market are actively engaged in pioneering solutions, such as subcutaneous injection, to gain a competitive advantage. Subcutaneous injections, also known as sub-q or SQ injections, involve delivering medication just beneath the skin. For instance, Eisai Co Ltd. and Nippon Medac Co Ltd. collaborated to launch the Metoject Subcutaneous Injection Syringe in November 2022. This product represents the first self-administrable prefilled syringe formulation of methotrexate (MTX) for rheumatoid arthritis approved in Japan. The Metoject Subcutaneous Injection Syringe is user-friendly, featuring a thin, 27-gauge needle for a more comfortable injection experience, a clear injection window, and a straightforward plunger mechanism to facilitate easy self-administration.

In October 2023, Amgen Plc, a prominent US-based biotechnology company, completed the acquisition of Horizon Therapeutic Plc for $27.8 billion. This strategic move enhances Amgen's inflammation portfolio by incorporating first-in-class, early-in-lifecycle medicines designed to treat rare inflammatory diseases. Horizon Therapeutic Plc, an Ireland-based biopharmaceutical company, specializes in providing treatments for focal segmental glomerulosclerosis, kidney transplant rejection, and rheumatoid arthritis drugs. This acquisition positions Amgen to strengthen its position in the market through a diversified and expanded product offering.

Major companies operating in the rheumatoid arthritis drugs market report are Pfizer Inc., Abbvie Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, F-Hoffmann La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Merck & Co Inc., Johnson & Johnson Inc., Bayer AG, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A, Biogen Inc., Regeneron Pharmaceuticals Inc., Galapagos NV, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, UCB S.A. Belgium., Astellas Pharma Inc., Corbus Pharmaceuticals Holdings Inc., Roche Holding AG, Daiichi Sankyo Company Limited, Chr. Hansen Holding A/S, Ipsen S.A, Mallinckrodt Pharmaceuticals, Gilead Sciences Inc.

North America was the largest region in the rheumatoid arthritis drugs market in 2023. North America is expected to be the fastest-growing region in the global rheumatoid arthritis market report during the forecast period. The regions covered in the rheumatoid arthritis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the rheumatoid arthritis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The rheumatoid arthritis drugs market consists of sales of products such as abatacept, aceclofenac and adalimumab. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Rheumatoid Arthritis Drugs Market Characteristics

3. Rheumatoid Arthritis Drugs Market Trends And Strategies

4. Rheumatoid Arthritis Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Rheumatoid Arthritis Drugs Market Size and Growth

  • 5.1. Global Rheumatoid Arthritis Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Rheumatoid Arthritis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Rheumatoid Arthritis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Rheumatoid Arthritis Drugs Market Segmentation

  • 6.1. Global Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Disease-Modifying Antirheumatic Drugs (DMARDs)
  • Biologic Response Modifiers (BRMs)
  • Other Drug Types
  • 6.2. Global Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Topical
  • Other Route Of Administrations
  • 6.3. Global Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

7. Rheumatoid Arthritis Drugs Market Regional And Country Analysis

  • 7.1. Global Rheumatoid Arthritis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Rheumatoid Arthritis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Rheumatoid Arthritis Drugs Market

  • 8.1. Asia-Pacific Rheumatoid Arthritis Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Rheumatoid Arthritis Drugs Market

  • 9.1. China Rheumatoid Arthritis Drugs Market Overview
  • 9.2. China Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Rheumatoid Arthritis Drugs Market

  • 10.1. India Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Rheumatoid Arthritis Drugs Market

  • 11.1. Japan Rheumatoid Arthritis Drugs Market Overview
  • 11.2. Japan Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Rheumatoid Arthritis Drugs Market

  • 12.1. Australia Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Rheumatoid Arthritis Drugs Market

  • 13.1. Indonesia Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Rheumatoid Arthritis Drugs Market

  • 14.1. South Korea Rheumatoid Arthritis Drugs Market Overview
  • 14.2. South Korea Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Rheumatoid Arthritis Drugs Market

  • 15.1. Western Europe Rheumatoid Arthritis Drugs Market Overview
  • 15.2. Western Europe Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Rheumatoid Arthritis Drugs Market

  • 16.1. UK Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Rheumatoid Arthritis Drugs Market

  • 17.1. Germany Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Rheumatoid Arthritis Drugs Market

  • 18.1. France Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Rheumatoid Arthritis Drugs Market

  • 19.1. Italy Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Rheumatoid Arthritis Drugs Market

  • 20.1. Spain Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Rheumatoid Arthritis Drugs Market

  • 21.1. Eastern Europe Rheumatoid Arthritis Drugs Market Overview
  • 21.2. Eastern Europe Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Rheumatoid Arthritis Drugs Market

  • 22.1. Russia Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Rheumatoid Arthritis Drugs Market

  • 23.1. North America Rheumatoid Arthritis Drugs Market Overview
  • 23.2. North America Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Rheumatoid Arthritis Drugs Market

  • 24.1. USA Rheumatoid Arthritis Drugs Market Overview
  • 24.2. USA Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Rheumatoid Arthritis Drugs Market

  • 25.1. Canada Rheumatoid Arthritis Drugs Market Overview
  • 25.2. Canada Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Rheumatoid Arthritis Drugs Market

  • 26.1. South America Rheumatoid Arthritis Drugs Market Overview
  • 26.2. South America Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Rheumatoid Arthritis Drugs Market

  • 27.1. Brazil Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Rheumatoid Arthritis Drugs Market

  • 28.1. Middle East Rheumatoid Arthritis Drugs Market Overview
  • 28.2. Middle East Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Rheumatoid Arthritis Drugs Market

  • 29.1. Africa Rheumatoid Arthritis Drugs Market Overview
  • 29.2. Africa Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Rheumatoid Arthritis Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Rheumatoid Arthritis Drugs Market Competitive Landscape
  • 30.2. Rheumatoid Arthritis Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. AbbVie Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Amgen Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Boehringer Ingelheim International GmbH
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Rheumatoid Arthritis Drugs Market Competitive Benchmarking

32. Global Rheumatoid Arthritis Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Rheumatoid Arthritis Drugs Market

34. Rheumatoid Arthritis Drugs Market Future Outlook and Potential Analysis

  • 34.1 Rheumatoid Arthritis Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Rheumatoid Arthritis Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Rheumatoid Arthritis Drugs Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer